Special Considerations in the Management of Autoimmune Hepatitis in COVID-19 Hotspots: A Review.
J Clin Transl Hepatol
; 9(4): 568-575, 2021 Aug 28.
Article
in English
| MEDLINE | ID: covidwho-1372168
ABSTRACT
The ongoing coronavirus disease-2019 (COVID-19) pandemic has necessitated special considerations in the management of diseases. The way presence of pre-existing diseases or treatment for it predisposes to, alters course of, and changes the management of COVID-19, is of relevance and is being extensively studied. Autoimmune hepatitis (AIH) is unique in that it is an autoimmune disease mandating treatment with immunosuppressive drugs, as well as a liver disease with potential for varying degrees of underlying fibrosis. The use of immunosuppressive drugs could alter the risk of acquiring COVID-19, the clinical course and severity of COVID-19 and the degree of underlying liver fibrosis could alter the clinical outcomes of patients with COVID-19. In this review, we try to summarize key areas relevant in understanding and improving the clinical care of patients with AIH in the current pandemic. Special considerations required in the management of patients with AIH in COVID-19 hotspots have been outlined based on the current evidence.
Full text:
Available
Collection:
International databases
Database:
MEDLINE
Type of study:
Prognostic study
Language:
English
Journal:
J Clin Transl Hepatol
Year:
2021
Document Type:
Article
Affiliation country:
Jcth.2021.00001
Similar
MEDLINE
...
LILACS
LIS